Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (25): 4673-4676.doi: 10.3969/j.issn.1673-8225.2010.25.028

Previous Articles     Next Articles

Controlled-release oxycodone hydrochloride tablets in combination with bisphosphonates for skeletal metastases-caused pain in 69 cases

Li Yu-Qing1, He Yan-bing2, Du Zhi-Qiang3   

  1. 1 Department of Oncology, 2 Department of Anesthesiology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou  510260, Guangdong Province, China; 3 Department of Oncology, Liwan Hospital Affiliated to Guangzhou Medical University, Guangzhou  510170, Guangdong Province, China
  • Online:2010-06-18 Published:2010-06-18
  • About author:Li Yu-qing★, Master, Associate chief physician, Department of Oncology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, Guangdong Province, China yuqinglee@21cn.com

PDF

482

Abstract:

BACKGROUND: Oxycodone hydrochloride is the medicine at the third step and is one of the most frequent medicines in treating severe cancer pain.
OBJECTIVE: To evaluate the efficacy and side effects of controlled-release oxycodone hydrochloride tablets and bisphosphonates on the treatment of skeletal metastases.
METHODS: A total of 69 patients suffering from skeletal metastases were treated with oral controlled-release oxycodone hydrochloride tablets, and the dosages were titrated according to the severity of pain. In addition, intravenous infusion of Zoledronic Acid was performed, 4 mg every 4 weeks. The efficacy and side effects of the treatment were evaluated after 2 cycles.
RESULTS AND CONCLUSION: Of the 69 patients, 25 cases (36.2%) achieved complete remission, 37 cases (53.6%) achieved partial remission, and 7 cases (10.1%) achieved minor remission．Pain relief was 89.9% (62/69). The side effects included constipation, nausea and vomiting, abdominal distention, anorexia, lethargy, dizziness, fever and muscle pain. Results show that the treatment using controlled-release oxycodone hydrochloride tablets and bisphosphonates is safe and effective for skeletal metastases. Its side effects are minor and tolerable．

CLC Number: